SOPHiA GENETICS SA (NASDAQ:SOPH) Receives Average Rating of “Hold” from Brokerages

SOPHiA GENETICS SA (NASDAQ:SOPH) has been assigned an average rating of “Hold” from the five brokerages that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $10.00.

Several research analysts recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. BTIG Research raised their price target on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. HC Wainwright boosted their price objective on SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Finally, Zacks Research upgraded SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st.

SOPHiA GENETICS Stock Down 0.9%

Shares of NASDAQ:SOPH opened at $7.61 on Friday. The business’s 50 day simple moving average is $6.98 and its two-hundred day simple moving average is $5.67. SOPHiA GENETICS has a 52-week low of $3.10 and a 52-week high of $8.98. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.55 and a current ratio of 2.69. The firm has a market cap of $638.40 million, a P/E ratio of -6.62 and a beta of 0.98.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). The business had revenue of $23.31 million for the quarter, compared to the consensus estimate of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. As a group, research analysts forecast that SOPHiA GENETICS will post -0.77 EPS for the current fiscal year.

Insider Buying and Selling at SOPHiA GENETICS

In other news, insider Zhenyu Xu sold 17,000 shares of the business’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $7.29, for a total transaction of $123,930.00. Following the completion of the transaction, the insider directly owned 590,887 shares in the company, valued at $4,307,566.23. The trade was a 2.80% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jurgi Camblong sold 50,069 shares of the business’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $5.80, for a total value of $290,400.20. Following the transaction, the chief executive officer owned 3,601,493 shares of the company’s stock, valued at approximately $20,888,659.40. The trade was a 1.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 342,592 shares of company stock valued at $2,205,587. Insiders own 4.88% of the company’s stock.

Hedge Funds Weigh In On SOPHiA GENETICS

Several institutional investors have recently modified their holdings of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in SOPHiA GENETICS by 246.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock valued at $25,341,000 after acquiring an additional 5,432,871 shares during the last quarter. Federated Hermes Inc. raised its stake in shares of SOPHiA GENETICS by 16.4% during the second quarter. Federated Hermes Inc. now owns 220,000 shares of the company’s stock valued at $682,000 after acquiring an additional 31,000 shares during the last quarter. Akre Capital Management LLC lifted its holdings in SOPHiA GENETICS by 66.2% in the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock worth $11,529,000 after buying an additional 1,481,636 shares during the period. Dimensional Fund Advisors LP lifted its stake in SOPHiA GENETICS by 24.7% in the third quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company’s stock worth $148,000 after acquiring an additional 6,205 shares during the period. Finally, Squarepoint Ops LLC bought a new stake in shares of SOPHiA GENETICS during the 3rd quarter valued at about $49,000. 31.59% of the stock is currently owned by institutional investors.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.